ECLS-SHOCK trial investigated the effect of early extracorporeal life support (ECLS) on mortality in patients with heart attack-induced cardiogenic shock who were planned for early revascularization. Patients were assigned to ECLS plus medical treatment or medical treatment alone. After 30 days, mortality rates were similar between groups (ECLS: 47.8%, Control: 49.0%). ECLS patients had more bleeding (23.4% vs. 9.6%) and vascular complications (11.0% vs. 3.8%). ECLS didn't lower 30-day mortality in patients with infarct-related cardiogenic shock.
Extracorporeal Life Support in Infarct-Related Cardiogenic Shock | NEJM
